PDGFRB and neoplasm: We recently determined that, in comparison to non-advanced BCC, aggressive BCC tumours presented an inflammatory cytokine profile that shifted to a Th2 cytokine inflammation profile, which is thought to be more tumour permissive [13] and may include pathways such as Toll-like receptor, PDGFR, and extracellular matrix remodeling [14].